In this issue:
Adalimumab biosimilar in moderate-tosevere chronic plaque psoriasis
IL-23 vs IL-17 inhibitors and incidental PsA
Biologics and risk of death and cardiovascular disease in psoriasis
Secukinumab in patients with moderate-to-severe HS
Anifrolumab for SLE
Risankizumab for moderate-to-severe PPP
QoL with lebrikizumab in moderate-to-severe AD
Bimekizumab or brodalumab for moderate-to-severe psoriasis
Infection rates with long-term dupilumab treatment in paediatric patients
Live-attenuated vaccine administration after methotrexate or dupilumab
Please login below to download this issue (PDF)